Navigation Links
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
Date:10/23/2007

-Encouraging signs of anti-tumor activity observed in patients with

medullary thyroid cancer-

SAN FRANCISCO, Oct. 23 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported encouraging data from an ongoing phase 1 trial of XL184, a potent inhibitor of MET, RET, and VEGFR kinases, in patients with advanced solid tumors or lymphoma. Anti-tumor activity has been observed in a variety of cancers at doses that are not associated with significant toxicity. Consistent with the anti-VEGFR activity of XL184, preliminary pharmacodynamic analyses show reductions in several biomarkers of angiogenesis. Data were presented today in a poster session (Abstract #A152) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held October 22-26, 2007 in San Francisco.

There were 33 patients available for safety, pharmacokinetic, and tumor response analyses as of the June 22, 2007 cutoff; further data were also provided for six additional patients after the cutoff. Of seven patients with medullary thyroid cancer (MTC), three have had partial responses (2 confirmed and 1 unconfirmed). Six of the seven patients had tumor shrinkage and one had non-measurable disease. All seven assessable patients with MTC experienced a rapid decrease in plasma levels of calcitonin, a marker frequently elevated in medullary thyroid cancer, and six of the seven patients had a decrease in the tumor marker carcinoembryonic antigen (CEA). All seven MTC patients are still on study. In addition, one patient with a neuroendocrine tumor has an unconfirmed partial response. In total, 15 patients with various solid malignancies or lymphoma have had stable disease
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
8. Media Advisory: ACC Updated Schedule
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... the acquisition of leading OTC brands from GSK in ... transaction is a clear demonstration of Perrigo,s unique ability ... distribution network spanning 36 countries.  Perrigo ... commented, "We are excited to complete this transaction, which ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
(Date:8/27/2015)... DURECT Corporation (Nasdaq: DRRX ) announced ... upcoming healthcare conferences.  , James ... the Rodman & Renshaw Investment Conference on Thursday, September ... being held at the St. Regis Hotel in ... webcast of the presentation will be available by accessing ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2
... , ALLEGAN, Mich., Nov. 19 Perrigo Company ... and CEO Joseph C. Papa will present at the Sidoti ... (EST) at the Grand Hyatt Hotel in New York City. ... supplier that develops, manufactures and distributes OTC and prescription pharmaceuticals, ...
... Nov. 19 Delcath Systems, Inc. (Nasdaq: DCTH ), ... (PHP(TM)) System, a minimally invasive drug delivery platform for the ... on the Company,s recent progress. , "Since we last communicated ... many significant milestones as we move into the first regulatory ...
Cached Medicine Technology:Delcath Systems Reports Substantial Progress 2Delcath Systems Reports Substantial Progress 3Delcath Systems Reports Substantial Progress 4
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, ... the treatment of prostate cancer, has announced the roll-out of its newest technology ... center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at ...
(Date:8/29/2015)... ... 30, 2015 , ... On September 30, 2015, the Career and Transfer Center ... accredited Maricopa Community Colleges , will be hosting a Job Expo to provide ... and opportunities. , The Expo has expanded to much more than just a typical ...
(Date:8/29/2015)... ... , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of Policy ... present an educational program titled “Asbestos and Your Health.” , The two and one ... at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA 19002. ...
(Date:8/29/2015)... ... August 29, 2015 , ... It can be ... against dribbled urine and sweat. "In order to prevent these problems, I conceived ... ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s crotch. It ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Dr. Tim ... mission. His mission is to increase acceptance of the chiropractic field in the ... that further debilitate them. Although Chiropractic was made available to the VA program ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring ... their risk of breast cancer. That is the warning ... ahead of print publication in the January issue of ... Practice . "No clinical trials have been published ...
... Australia, cancer incidence rates have increased while deaths from cancer ... a recent study published early online in the Asia-Pacific ... disease group, cancer has the greatest overall impact on Australians, ... in five dying from it before the age of 85. ...
... early-stage HER2-positive breast cancer may have worse ... Mayo Clinic researchers found in a study presented today ... Symposium . HER2-positive breast cancer gets its name from ... that promotes cancer cell growth. "Not only did ...
... the results of a new study published in the ... African-Americans, Hispanics and uninsured patients use fewer post-hospitalization services ... care, and rehabilitation. Notably, the authors found ... a few categories, while disparities were highest among the ...
... HealthDay Reporter , WEDNESDAY, Dec. 7 (HealthDay News) -- Multiple ... and work its way into the deep interior, according to ... system disease. The new findings, which could spur changes ... solidify a theory that,s emerged in recent years. This new ...
... in children or adults, often takes place even in ... obesity. Current methods to treat such overeating in ... eat, requiring them to track their food intake and ... such behavioral therapy techniques don,t work long term, according ...
Cached Medicine News:Health News:Women advised to avoid ZEN bust-enhancing supplements because of possible cancer risk 2Health News:Study sheds light on cancer burden in Australia 2Health News:Mayo Clinic: Obese patients with HER2-positive breast cancer may have worse outcomes 2Health News:Racial, ethnic and insurance disparities revealed in post-hospital care after trauma 2Health News:Racial, ethnic and insurance disparities revealed in post-hospital care after trauma 3Health News:MS May Take a Different Pathway Than Previously Thought 2Health News:MS May Take a Different Pathway Than Previously Thought 3Health News:New approach to management of overeating in children 2Health News:New approach to management of overeating in children 3
... Now there is a more efficient ... first fully portable battery operated patient ... and surgical teams with a compact ... throughout the entire surgical process. Its ...
... CSZ safely provides effective air warming therapy ... patented design of our WarmAir® FilteredFlo® blankets, ... which supplies gently moving, clean air that ... contaminants to your patient or staff. All ...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Medicine Products: